- TRADE NAMES: PT-141; Vyleesi (AMAG Pharmaceuticals)
- INDICATIONS: Treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder.
- CLASS: Melanocortin receptor agonist
- HALF-LIFE: ~2.7 hours
- FDA APPROVAL DATE: 06/21/2019
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Naltrexone - PREGNANCY: Advise patients to discontinue treatment if pregnancy is suspected.
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
